There is a conversation that happens constantly in the early days of building something this country has never quite had before, and it is not really a pitch. It is an explanation. Repeated to almost everyone, over and over, for what feels like years.
To investors, explaining patiently that obesity is a chronic clinical condition, not a wellness fad about to be replaced by the next fitness app. To patients, explaining that what they actually need is real medical care, something sustained, not yet another diet plan with a fresh coat of paint on it. To a healthcare system built for decades around fevers, fractures, infections, things that come and go, explaining why a slow, stubborn, deeply stigmatised condition like obesity needs an entire infrastructure of its own rather than a few rushed minutes during a routine check-up.
That explanation, in boardrooms, in clinics, in patients’ living rooms, was most of what the early years of this work actually looked like.
The numbers finally became impossible to brush aside.
Obesity in India sat for a long time in that strange category of things everyone half-acknowledged and nobody treated with real urgency. That is shifting now, and shifting fast. Close to 29 percent of adults in urban India are currently living with obesity, with rural India at over 16 percent, and both figures are climbing well ahead of earlier predictions. By 2050, India could be home to more than 440 million people who are overweight or obese, a number large enough that it stops sounding like a statistic and starts sounding like a description of where the country’s health system is heading.
Look at what sits underneath that figure and it gets harder to look away from. India’s diabetic population crossed 200 million in 2025, the highest of any country in the world. Roughly 38 percent of Indian adults are now believed to be living with non-alcoholic fatty liver disease. Hypertension, PCOS, and several obesity-linked cancers are turning up in age groups that would have seemed completely low-risk just ten years back. None of this sits apart from obesity. It grows directly out of it.
Care that simply was not there.
Before anything resembling structured digital obesity care existed here, someone genuinely trying to deal with this condition had painfully few real choices. A GP visit that wrapped up with a printed diet chart and a vague nudge to walk more. A specialist appointment, usually tucked away in a big city, that required both spare money and the ability to travel for it. Or, for the most severe cases, bariatric surgery.
Everyone caught in between, and this was most people who actually needed support, simply had nowhere to go. No programme stitching together a physician, a dietitian, behavioural support, and medication oversight across the months and years this kind of care genuinely takes. That was not a small gap in the system. That basically was the system, as far as obesity was concerned.
Why digital was never really a choice.
India’s sheer size makes this question answer itself. A clinic in Pune, however excellent, cannot give someone living in Patna the kind of regular, dependable contact that managing a chronic condition demands over time. Telemedicine use in India had already crossed 120 million consultations annually by 2025, growing fastest in exactly the tier two and tier three cities where specialist access has always been thinnest. The pipes for remote healthcare already existed. What had never been built through them was a model shaped specifically around obesity.
Then the medications showed up.
Semaglutide and Tirzepatide entered Indian clinical practice through 2024 and picked up serious pace through 2025. Prescriptions for obesity-related medication among Indian doctors more than doubled in a single year. For the first time at any meaningful scale, obesity was being spoken about publicly as something medicine could actually treat, rather than something a person was simply expected to manage alone through sheer willpower.
But a prescription handed over on its own rarely produces lasting results. The evidence keeps pointing the same direction. GLP-1 medications work considerably better when nutrition is actively managed alongside them, when muscle mass is being tracked instead of ignored, and when real behavioural support sits underneath the treatment rather than nowhere at all. The medications opened a door the country was not yet ready to properly walk people through.
What those early years actually taught.
Almost everyone who arrives at a digital obesity programme has already tried something else first. A diet that worked beautifully for six weeks and then quietly fell apart. A gym membership that got used twice and then forgotten. They show up carrying scepticism, and it is scepticism they earned honestly through experience, not something unfair. The only thing that genuinely moves that scepticism is honest talk about real outcomes, not confident marketing language wearing a stethoscope around its neck.
Heading into 2026, corporate wellness programmes, insurers, and government health policy are all beginning to treat obesity as something that deserves direct attention rather than a quiet footnote behind other diagnoses. A market that had to be built from almost nothing is now taking shape, and taking shape quickly.
Being early in a market like this does not really hand you customers first. It hands you something more valuable. Time to build the thing properly, before everyone else is even paying attention.
<p>The post Building a medtech startup in a market that didn’t exist: Lessons from creating India’s digital obesity care ecosystem first appeared on Hello Entrepreneurs.</p>
Comments are closed.